RESEARCH NOTICE & LEGAL DISCLAIMER

FOR RESEARCH PURPOSES ONLY. All information provided within the Biolabs Peptides Research Centre is intended strictly for scientific, laboratory, and educational purposes.

Not Medical Advice: The protocols and data presented herein do not constitute medical advice, nursing advice, or a professional healthcare diagnosis.
Non-Therapeutic: These peptides are not intended to diagnose, treat, cure, or prevent any medical condition or disease.
Researcher Responsibility: Any research conducted should be performed by qualified professionals in a controlled laboratory environment. By accessing this data, you acknowledge that you are responsible for following your local laws and institutional safety guidelines.

GODZILLA
20MG

HIGHLIGHTS

Retatrutide (LY3437943) represents the "triple-agonist" frontier in metabolic research. It is a single peptide that targets three essential receptor pathways: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and the Glucagon receptor. By activating this "triple crown" of metabolic signaling, Retatrutide is studied for its unprecedented ability to increase energy expenditure, suppress appetite, and promote significant weight loss in research models, outperforming single and dual-agonist predecessors.

Retatrutide 20 mg Vial: Dosage & Titration Protocol

Retatrutide is a potent "triple-agonist" peptide. To ensure proper tolerability and minimize gastrointestinal side effects, a steady titration (dose escalation) schedule is recommended.

1. Reconstitution (Mixing)

Diluent: Add 2.0 mL of Bacteriostatic Water to your 20 mg vial.
Concentration: This creates a 10 mg/mL solution.
Measurement: On a standard U-100 (1 mL) insulin syringe:
- 5 Units = 0.5 mg
- 10 Units = 1.0 mg
- 20 Units = 2.0 mg
- 40 Units = 4.0 mg

2. The Titration Schedule

(Doses are administered via subcutaneous injection once per week)

Phase 1: Initiation (Weeks 1 through 4)

Weekly Dose: 2 mg
Syringe Volume: 20 Units

Phase 2: Escalation (Weeks 5 through 8)

Weekly Dose: 4 mg
Syringe Volume: 40 Units

Phase 3: Maintenance (Weeks 9 through 12)

Weekly Dose: 6 mg
Syringe Volume: 60 Units

Phase 4: Maximum Dose (Weeks 13 and beyond)

Weekly Dose: 8 mg
Syringe Volume: 80 Units

3. Administration & Storage

Method: Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites every week to prevent skin irritation.
Frequency: Once every 7 days, ideally on the same day each week.
Storage: Keep unopened vials in the freezer. Once reconstituted (mixed), store in the refrigerator and use within 28 days.

4. Side Effects & Management

Common Effects: Nausea, diarrhea, or appetite suppression.
Adjustment: If side effects are difficult to manage, do not increase the dose. Stay at the current level for an additional 4 weeks until your body adjusts.
Hydration: Ensure high water intake and prioritize protein consumption to protect lean muscle mass.

SAHPRA COMPLIANCE & LEGAL DISCLAIMER

ATTENTION: This product is NOT REGISTERED with the South African Health Products Regulatory Authority (SAHPRA).

This medicine has not been evaluated by SAHPRA for its quality, safety, or intended use.
Retatrutide is currently an investigational compound and is not approved for the treatment of obesity, diabetes, or any other medical condition in South Africa.
In terms of the Medicines and Related Substances Act (Act 101 of 1965), the use of unregistered medicines is generally restricted to authorized clinical trials or specific Section 21 authorizations.
WARNING: Compounded GLP-1, GIP, or Glucagon agonists have been flagged by SAHPRA as potentially "undesirable" due to risks of contamination, incorrect dosing, and lack of sterile oversight. Use of this substance is at the user’s own risk. Consult a registered medical practitioner before use.

Medical Notice: This document is for informational purposes only and does not replace professional medical advice. If you experience heart palpitations, severe abdominal pain, or persistent vomiting, discontinue use and seek immediate medical attention.